한글목차

항결핵 치료제의 동향과 예측

세계 항결핵 치료제 시장은 2024년부터 2030년까지 복합 연간 성장률(CAGR) 7.1%를 나타낼 전망이며 2030년에는 21억 달러에 달할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 결핵 유병률 증가, 결핵 계발에 대한 정부 조직의 이니셔티브 증가, 신흥 국가의 MDR 및 XDR 사례의 급증입니다. 세계의 항결핵 치료제 시장의 미래는 병원, 전문 클리닉, 재택치료 시장에서의 기회에 의해 유망시되고 있습니다.

항결핵 치료제 시장 인사이트

Lucintel의 예측은 결핵 환자 증가와 결핵 치료에 대한 이소니아지드의 채용 증가로 이소니아지드가 예측 기간 동안 가장 높은 성장을 이룰 전망입니다.

이 시장에서 병원은 가장 큰 부문로 계속 될 것입니다.

아시아태평양은 정부 이니셔티브의 확대, 제너릭 제조업체 증가, 이 지역에서의 헬스케어 인프라의 지속적인 개발에 의해 예측 기간 동안 가장 높은 성장이 예상됩니다.

이 보고서는 다음 11가지 주요 질문에 답변합니다.

• Q.1. 시장 부문 중 가장 유망하고 고성장하는 기회는 무엇인가?
• Q.2. 어떤 부문이 더 빠른 속도로 성장하는지, 그리고 그 이유는?
• Q.3. 앞으로 성장이 가속될 것으로 보이는 지역과 그 이유는?
• Q.4. 시장 역학에 영향을 미치는 주요 요인은? 시장의 주요 과제와 비즈니스 리스크는?
• Q.5. 이 시장에서의 비즈니스 리스크와 경쟁 위협은?
• Q.6. 이 시장에서의 새로운 동향과 그 이유는?
• Q.7. 시장에서 고객 수요 변화에는 어떤 것이 있는가?
• Q.8. 이 시장에서의 새로운 개발과 그 개발을 리드하고 있는 기업은?
• Q.9.이 시장의 주요 기업은? 주요 기업은 사업 성장을 위해 어떤 전략적 노력을 추진하고 있는가?
• Q.10. 이 시장에서 경쟁 제품은 어떠한 것이며, 재료 및 제품의 대체로 인한 시장 점유율 저하의 위협은 어느 정도입니까?
• Q.11. 지난 5년 동안 어떤 M&D가 수행되었고 업계에 어떤 영향을 미쳤는가?

목차

제1장 주요 요약

제2장 세계의 항결핵약 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 2018년부터 2030년까지 시장 동향과 예측 분석

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 항결핵약 시장 동향(2018-2023)과 예측(2024-2030)
• 유형별 세계의 항결핵 치료제 시장
  • 활동성 결핵
  • 잠재성 결핵
  • 기타
• 약물 클래스별 세계의 항결핵약 시장
  • 이소니아지드
  • 리펀핀
  • 에산부톨
  • 피라지나미드
  • 플루오로퀴놀론류
  • 베다 기린
  • 아미노글리코시드
  • 티오아미드
  • 환상 펩티드
• 최종 용도별 세계의 항결핵 치료제 시장
  • 병원
  • 전문 클리닉
  • 홈케어
  • 기타

제4장 2018년부터 2030년까지 지역별 시장 동향과 예측 분석

• 지역별 세계의 항결핵약 시장
• 북미의 항결핵약 시장
• 유럽의 항결핵약 시장
• 아시아태평양 항결핵 치료제 시장
• 기타 지역 항결핵 치료제 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영상의 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 유형별 세계의 항결핵 치료제 시장의 성장 기회
  • 의약품 클래스별 세계의 항결핵 치료제 시장의 성장 기회
  • 최종 용도별 세계의 항결핵 치료제 시장의 성장 기회
  • 지역별 세계의 항결핵 치료제 시장의 성장 기회
• 세계의 항결핵약 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 항결핵 치료제 시장의 능력 확대
  • 세계의 항결핵 치료제 시장에서의 합병, 인수, 합작 사업
  • 인증 및 라이센스

제7장 유력 기업의 기업 프로파일

• Lupin
• Macleods
• 오츠카
• Johnson & Johnson
• Sequella
• Novartis
• Akorn
• Fresenius SE
• Viatris

영문목차

Anti-Tuberculosis Therapeutics Trends and Forecast

The future of the global anti-tuberculosis therapeutics market looks promising with opportunities in the hospital, specialty clinic, and homecare markets. The global anti-tuberculosis therapeutics market is expected to reach an estimated $2.1 billion by 2030 with a CAGR of 7.1% from 2024 to 2030. The major drivers for this market are growing prevalence of tuberculosis, increasing initiative from government organization towards tuberculosis awareness, and surging incidence of MDR and XDR cases in developing countries.

A more than 150-page report is developed to help in your business decisions.

Anti-Tuberculosis Therapeutics by Segment

The study includes a forecast for the global anti-tuberculosis therapeutics by type, drug classes, end use, and region.

Anti-Tuberculosis Therapeutics Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Active TB
• Latent TB
• Others

Anti-Tuberculosis Therapeutics Market by Drug Classes [Shipment Analysis by Value from 2018 to 2030]:

• Isoniazid
• Rifampin
• Ethambutol
• Pyrazinamide
• Fluoroquinolones
• Bedaquiline
• Amynoglycosides
• Thioamides
• Cyclic Peptides
• Others

Anti-Tuberculosis Therapeutics Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Specialty Clinics
• Homecare
• Others

Anti-Tuberculosis Therapeutics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Anti-Tuberculosis Therapeutics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies anti-tuberculosis therapeutics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the anti-tuberculosis therapeutics companies profiled in this report include-

• Lupin
• Macleods
• Otsuka
• Johnson & Johnson
• Sequella
• Novartis
• Akorn
• Fresenius Se
• Viatris

Anti-Tuberculosis Therapeutics Market Insights

Lucintel forecasts that isoniazid is expected to witness highest growth over the forecast period due to increasing cases of tuberculosis and rising adoption of isoniazid for the treatment of tuberculosis.

Within this market, hospitals will remain the largest segment due to .

APAC is expected to witness highest growth over the forecast period due to growing government intiatives, increasing number of generic manufacturers, and on-going development of healthcare infrastructure in the region.

Features of the Global Anti-Tuberculosis Therapeutics Market

Market Size Estimates: Anti-tuberculosis therapeutics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Anti-tuberculosis therapeutics market size by type, drug classes, end use, and region. in terms of value ($B).

Regional Analysis: Anti-tuberculosis therapeutics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, drug classes, end uses, and region.s for the anti-tuberculosis therapeutics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the anti-tuberculosis therapeutics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the anti-tuberculosis therapeutics market size?

Answer: The global anti-tuberculosis therapeutics market is expected to reach an estimated $2.1 billion by 2030.

Q.2. What is the growth forecast for anti-tuberculosis therapeutics market?

Answer: The global anti-tuberculosis therapeutics market is expected to grow with a CAGR of 7.1% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the anti-tuberculosis therapeutics market?

Answer: The major drivers for this market are growing prevalence of tuberculosis, increasing initiative from government organization towards tuberculosis awareness, and surging incidence of MDR and XDR cases in developing countries.

Q.4. What are the major segments for anti-tuberculosis therapeutics market?

Answer: The future of the anti-tuberculosis therapeutics market looks promising with opportunities in the hospital, specialty clinic, and homecare markets.

Q.5. Who are the key Anti-Tuberculosis Therapeutics Market companies?

Answer: Some of the key anti-tuberculosis therapeutics companies are as follows:

• Lupin
• Macleods
• Otsuka
• Johnson & Johnson
• Sequella
• Novartis
• Akorn
• Fresenius SE
• Viatris

Q.6. Which anti-tuberculosis therapeutics market segment will be the largest in future?

Answer: Lucintel forecasts that isoniazid is expected to witness highest growth over the forecast period due to increasing cases of tuberculosis and rising adoption of isoniazid for the treatment of tuberculosis.

Q.7. In anti-tuberculosis therapeutics market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness highest growth over the forecast period due to growing government intiatives, increasing number of generic manufacturers, and on-going development of healthcare infrastructure in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the anti-tuberculosis therapeutics market by type (active TB, latent LB, and others), drug classes (isoniazid, rifampin, ethambutol, pyrazinamide, fluoroquinolones, bedaquiline, amynoglycosides, thioamides, cyclic peptides, and others), end use (hospitals, specialty clinics, homecare, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Anti-Tuberculosis Therapeutics Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Anti-Tuberculosis Therapeutics Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Anti-Tuberculosis Therapeutics Market by Type
  • 3.3.1: Active TB
  • 3.3.2: Latent TB
  • 3.3.3: Others
• 3.4: Global Anti-Tuberculosis Therapeutics Market by Drug Classes
  • 3.4.1: Isoniazid
  • 3.4.2: Rifampin
  • 3.4.3: Ethambutol
  • 3.4.4: Pyrazinamide
  • 3.4.5: Fluoroquinolones
  • 3.4.6: Bedaquiline
  • 3.4.7: Amynoglycosides
  • 3.4.8: Thioamides
  • 3.4.9: Cyclic Peptides
• 3.5: Global Anti-Tuberculosis Therapeutics Market by End Use
  • 3.5.1: Hospitals
  • 3.5.2: Specialty Clinics
  • 3.5.3: Homecare
  • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Anti-Tuberculosis Therapeutics Market by Region
• 4.2: North American Anti-Tuberculosis Therapeutics Market
  • 4.2.2: North American Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
• 4.3: European Anti-Tuberculosis Therapeutics Market
  • 4.3.1: European Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
  • 4.3.2: European Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
• 4.4: APAC Anti-Tuberculosis Therapeutics Market
  • 4.4.1: APAC Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
  • 4.4.2: APAC Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
• 4.5: ROW Anti-Tuberculosis Therapeutics Market
  • 4.5.1: ROW Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
  • 4.5.2: ROW Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Type
  • 6.1.2: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Drug Classes
  • 6.1.3: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by End Use
  • 6.1.4: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Region
• 6.2: Emerging Trends in the Global Anti-Tuberculosis Therapeutics Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Anti-Tuberculosis Therapeutics Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Anti-Tuberculosis Therapeutics Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Lupin
• 7.2: Macleods
• 7.3: Otsuka
• 7.4: Johnson & Johnson
• 7.5: Sequella
• 7.6: Novartis
• 7.7: Akorn
• 7.8: Fresenius SE
• 7.9: Viatris